AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04786691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black
Description: No Creamer
Study NCT06311461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncturist will swab each point with alcohol. Needles will be inserted and retained for 30 minutes. Each needle will be rotated 3 times to stimulate the qi in the meridian; 10 minutes after insertion, 20 minutes after insertion, and just prior to removal at 30 minutes. Needles will be inserted using the standards of clean needle technique established by the Council of Colleges of Acupuncture and Oriental Medicine. One size acupuncture needle, 0.25 diameter × 40 mm length, will be used. All acupuncture needles are sterile, disposable, and made of surgical stainless steel with stainless steel wound heads. Sessions will be repeated twice weekly (with at least 2 off days in between) for 5 weeks (10 sessions).
Study NCT06311461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Viewing non-pain related TED talk videos over 5 weeks approximately equal to 10 hours of treatment for the acupuncture group.
Study NCT05892250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Manual techniques and therapeutic exercise
Study NCT05892250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy + Dynamic Humeral Centering exercises
Description: Manual techniques and therapeutic exercise and active dynamic humeral centering exercises
Study NCT04485728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Improvement Protocol Intervention for Hospitalized Antepartum Patients
Description: Patients are getting sleep hygiene education and a sleep hygiene kit.
Study NCT05199922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M TAPA block
Description: Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 40 ml (20 ml for each side) of %0,25 bupivacaine.
Study NCT03338764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-1
Description: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep
Study NCT03338764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
Study NCT05947669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab is available in vials of 100 mg with pharmaceutical form of concentrate for solution for infusion. Participating sites will ensure availability of infliximab as part of the hospital's standard supply for use in the study.
Study NCT05947669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.
Study NCT05947669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.
Study NCT05947669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.
Study NCT05947669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.
Study NCT05394285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: The first chemotherapy cycle (single center, open label, randomized controlled):~When platelets were \<50\*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is >100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days.
Study NCT05394285 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hetrombopag
Description: The first chemotherapy cycle (single center, open label, randomized controlled):~When platelets were \<50\*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is >100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days.
Study NCT05394285 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rh-TPO
Description: The first chemotherapy cycle (single center, open label, randomized controlled):~Start using rh-TPO 15000 units/day (subcutaneous injection) when platelets are less than 50\*109/L. When the platelet count is more than 100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days.
Study NCT02503163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809 ophthalmic solution
Study NCT05594602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-235
Description: Subjects will receive EDP-235 on Days 1 and 14
Study NCT05594602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-235
Description: Subjects will receive EDP-235 on Days 1 and 23
Study NCT05594602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-235
Description: Subjects will receive EDP-235 on Days 1 and 8
Study NCT06612723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity gait training
Description: Individuals will perform up to 40 minutes of walking practice during 60 minute sessions while targeting heart rates of at least 70% heart rate reserve.
Study NCT06612723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity gait training
Description: Individuals will perform up to 40 minutes of walking practice during 60 minute sessions while targeting heart rates of at least 70% heart rate reserve.
Study NCT05594602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will receive itraconazole QD Days 5-18
Study NCT05594602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Subjects will receive carbamazepine BID Days 5-23 and Days 24-27
Study NCT06612723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity coaching
Description: Individuals will receive feedback on the minutes of walking activity performed on non-training days and provided coaching strategies to increase this metric.
Study NCT06612723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity coaching
Description: Individuals will receive feedback on the minutes of walking activity performed on non-training days and provided coaching strategies to increase this metric.
Study NCT06611709 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham taping (non-elastic medical cloth tape)
Description: sham taping
Study NCT06611709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping: A standard 5-cm wide KinesioⓇ Tex Gold
Description: A standard 5-cm wide KinesioⓇ Tex Gold
Study NCT06611709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: home-based exercises
Study NCT06611709 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exercises
Description: home-based exercises
Study NCT05594602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Subjects will receive quinidine BID Days 5-12
Study NCT05251142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: Jumps in place. Some examples include multiple vertical jumps while reaching an overhead object, squat jump, pike jump, or tuck jump.~* Standing jumps. Examples include the single leg jump, maximal vertical jump ,standing long jump or lateral long jump.~* Multiple hops and jumps. Examples would include multiple long jumps or cone hops performed in succession, such as 5 hops in a row~* Box drills. Examples of these drills include box jumps ,repeated box jumps, and single leg box jumps.~* Depth jumps. Examples include stepping off the box and landing, stepping off the box and jumping vertically immediately after landing, or stepping off the box, landing, and sprinting.
Study NCT05251142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General exercises
Description: Dumbbell Squat: 3 sets of 15 reps, Dumbbell Alternating Bench Press: 3 sets of 15 reps, Straight Arm Pulldowns: 3 sets of 15 reps, Dumbbell Front Raises: 3 sets of 15 reps, Reverse Flyes: 3 sets of 15 reps, Overhead Tricep Extensions: 3 sets of 15 reps, Dumbbell Bicep Curls: 3 sets of 15 reps, Jackknife Crunches: 3 sets of 20 reps, Oblique Crunches: 3 sets of 20 reps, External Rotation: 3 sets of 15 reps
Study NCT06019559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and K-833
Description: Both administered orally
Study NCT06019559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and matching placebo to K-833
Description: Both Administered orally
Study NCT06019559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to K-757 and matching placebo to K-833
Description: Both administered orally
Study NCT05674162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unobserved
Description: Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher.
Study NCT05674162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observed
Description: Participants walk a distance of 40 meters wearing the sensors, observed by the researcher.
Study NCT05674162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Unobserved & Measured
Description: Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher and aware of the gait measurement by the sensors.
Study NCT04588129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-102
Description: (N-Methyl amisulpride)
Study NCT05153876 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Headache attack descriptions, Headache related disability descriptions, Questionnaires, MIDAS, MSQv2.1, SF36
Study NCT06094946 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine Hydrocloride
Description: 1 mg/ml
Study NCT06094946 — intervention group
Intervention type: DRUG
Intervention: Fentanyl Citrate
Description: 2.5 micrograms/ml
Study NCT04445740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i♥rhythm project
Description: behavioral mobile health intervention, targeting parents of 5-8 year olds, designed to promote consistent behavioral rhythms in children through consistent bedtimes, light exposure, meal timing, and physical activity.
Study NCT05275933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TCM intervention
Description: Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
Study NCT05275933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Placebo Capsules (PC) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
Study NCT06338943 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography to diagnose HFpEF
Study NCT06338943 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire to determine the presence of adverse pregnancy outcomes history
Study NCT04610138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-ZnAg
Description: ZnAg liquid solution
Study NCT04610138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water
Study NCT06119165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental nudges
Description: Participants will view protein, frozen meal, and snack products with eco-labels applied. For each category, they will then be instructed to select 1 item from that category they wish most to purchase. Categories will be shown in random order. If a participant selects a product with a red eco-label, they will be shown a peer comparison message and will be given an opportunity to switch to a product with a yellow or green eco-label.
Study NCT05098327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: pioglitazone 30 mg dose 1 tab daily will be given for 12 weeks
Study NCT05098327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills containing cellulose 1 pill daily will be given for 12 weeks
Study NCT05219968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYR-210
Description: LYR-210 drug matrix (mometasone furoate)
Study NCT05219968 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham procedure control
Description: Sham procedure control
Study NCT05219968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Therapy
Description: Daily Saline Irrigation
Study NCT05219968 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Background Therapy
Description: Daily Saline Irrigation
Study NCT06184009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALL, High risk
Description: Intervention Description :~* Clinical and genetic factors consistent with High risk : Induction → Consolidation~  1. BM MRD \&lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~ 2. BM MRD ≥ 0.01% after Induction, \&lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~ 3. BM MRD ≥ 0.01% after Consolidation~  <!-- -->~  1. T cell ALL : Change to very high risk regimen~ 2. Pre-B ALL : IM #1 → Intensification~     1. BM MRD \&lt; 0.01% after IM #1 : Continue with \&#39;No. 2\&#39; of High risk regimen starting with DI #1~    2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~        * T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported.
Study NCT05534243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard neuromuscular blocker practices
Description: Usual care neuromuscular blocker in the ED
Study NCT05534243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Nurses and physicians will be engaged regarding the clinical outcome data on the importance of shorter acting neuromuscular blockers, and the objectives of the research. Education will include in-services and lectures focused on the importance of neuromuscular blocker protocols on patient outcome. The use of neuromuscular blokers will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based neuromuscular blocker protocols.
Study NCT05438342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adoptive immune cells
Description: Immunotherapy Mononuclear cells were collected from 50ml peripheral blood , and cultured adoptive immune cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion.
Study NCT05438342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotron RF-8EX
Description: Hyperthermia for 40-50 minutes
Study NCT05438342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermotron RF-8EX
Description: Hyperthermia for 40-50 minutes
Study NCT05438342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy，checkpoint immunotherapy, targeted therapy
Description: The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines
Study NCT05438342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy，checkpoint immunotherapy, targeted therapy
Description: The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines
Study NCT04710680 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05581823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets
Study NCT05581823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Extended-release oral tablets
Study NCT05275465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-006
Description: Different dose levels of HH-006
Study NCT05275465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Different dose levels of placebo
Study NCT06171529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTM
Description: CTM Flow is stored in 1cc vials and is stable at room temperature and does not need to be refrigerated. CTM Flow will be supplied to and stored at the IHTSC Beltway Surgery Center. Product will be stored at room temperature without continued temperature control. All product will be kept in the Beltway Surgery Center and will not be separated from the marketed non-study CTM. Treating Surgeons will remain blinded to the treatment group, but will ensure that only the injection is billed to patients and the CTM or saline are provided at no cost. Lexie Reissaus, CCRP will track drug accountability.
Study NCT06171529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo/Saline control injection
Study NCT04762199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flt3/MerTK Inhibitor MRX-2843
Description: Given PO
Study NCT04762199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study NCT05171114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of joint amplitudes
Description: Measurement of joint amplitudes by goniometry of the MCP, IPP, IPD for 2, 3, 4 and 5th radii, 1st commissure spacing and Kapandji score for the thumb
Study NCT04391777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fourth ventricle compression technique (CV-4)
Description: The participant is in the supine position and the principal investigator is seated at the patient's head, with elbows resting on the table. The main investigator overlaps his hands with the thenar eminences, contacting the occipital bone squamous part, between the external occipital protuberance and the participant's occipito-mastoid suture. The technique begins with a maintained compression on the occipital squamous part during a deep thorax exhalation. Throughout the compression of the occipital bone and the participant's voluntary inspirations, the principal investigator feels a gradual pressure increase at the thenar eminences. The technique will be performed until reaching the still point, in which the mobility of the occipital bone, respiratory rate and muscle tone decrease, or until 5 minutes elapsed.
Study NCT04391777 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The main investigator uses the technique contact but does not perform any type of tissue traction or compression, maintaining this contact for 5 minutes. At the end of the stipulated time, the contact is removed in a subtle way.
Study NCT05225025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROSE
Description: The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is an evidence-based intervention that has been proven to reduce cases of post-partum depression among low-income and racially and ethnically diverse women.~ROSE is administered to pregnant women in small group settings, typically in the same location that prenatal care is being provided (in this study, a hospital setting). It is divided into four 90-minute group sessions and teaches interpersonal psychotherapy-based skills that mitigate identified risk factors for PPD such as social support, stress management skills and communication.~ROSE curriculum will be implemented using groups in a continuous cycle, with patients entering into the intervention curriculum at the time of their enrollment and continuing through until all 4 total sessions have been accomplished.
Study NCT05225025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Usual hospital care with no behavioral intervention